Related News
Gene find could lead to chronic pain drugs
Source: Agencies |
September 10, 2011, Saturday
|
Print Edition
Print Edition
BRITISH scientists have identified a gene responsible for regulating chronic pain, called HCN2, and say their discovery should help drug researchers in their search for more effective, targeted pain-killing medicines.
Scientists from Cambridge University said that if drugs could be designed to block the protein produced by the gene, they could treat a type of pain known as neuropathic pain, which is linked to nerve damage and often very difficult to control with currently available drugs.
"Our research lays the groundwork for the development of new drugs to treat chronic pain by blocking HCN2," said Peter McNaughton of Cambridge's pharmacology department, who led the study.
Pain is estimated to cost more than 200 billion euros (US$281 billion) a year in Europe and US$150 billion a year in the United States.
Studies show that around 22 percent of people with chronic pain become depressed and 25 percent go on to lose their jobs. Scientists have known about the HCN2 gene, which is found in pain-sensitive nerve endings, but had not yet fully understood its role in regulating pain.
Because a related gene called HCN4 plays a critical role in controlling electrical activity in the heart, McNaughton's team suspected that HCN2 might have a similar function and regulate electrical activity in pain-sensitive nerves.
For the study, published in the journal Science on Thursday, the researchers engineered the removal of the HCN2 gene from pain-sensitive nerves and then used electrical stimuli on these nerves in lab dishes to find out how the nerves had been changed by the removal of HCN2.
The scientists then studied genetically modified mice in which the HCN2 gene had been deleted. By measuring the speed the mice withdrew from different types of painful stimuli, the scientists were able to show that deleting the HCN2 gene took away neuropathic pain.
They found that deleting HCN2 appeared to have no effect on normal acute pain, a factor they said was important since this type of pain acts as a useful warning signal to the body.
Scientists from Cambridge University said that if drugs could be designed to block the protein produced by the gene, they could treat a type of pain known as neuropathic pain, which is linked to nerve damage and often very difficult to control with currently available drugs.
"Our research lays the groundwork for the development of new drugs to treat chronic pain by blocking HCN2," said Peter McNaughton of Cambridge's pharmacology department, who led the study.
Pain is estimated to cost more than 200 billion euros (US$281 billion) a year in Europe and US$150 billion a year in the United States.
Studies show that around 22 percent of people with chronic pain become depressed and 25 percent go on to lose their jobs. Scientists have known about the HCN2 gene, which is found in pain-sensitive nerve endings, but had not yet fully understood its role in regulating pain.
Because a related gene called HCN4 plays a critical role in controlling electrical activity in the heart, McNaughton's team suspected that HCN2 might have a similar function and regulate electrical activity in pain-sensitive nerves.
For the study, published in the journal Science on Thursday, the researchers engineered the removal of the HCN2 gene from pain-sensitive nerves and then used electrical stimuli on these nerves in lab dishes to find out how the nerves had been changed by the removal of HCN2.
The scientists then studied genetically modified mice in which the HCN2 gene had been deleted. By measuring the speed the mice withdrew from different types of painful stimuli, the scientists were able to show that deleting the HCN2 gene took away neuropathic pain.
They found that deleting HCN2 appeared to have no effect on normal acute pain, a factor they said was important since this type of pain acts as a useful warning signal to the body.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
